Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

An integrated physiology-based model for the interaction of RAA system biomarkers with drugs.

Ramusovic S, Laeer S.

J Cardiovasc Pharmacol. 2012 Nov;60(5):417-28. doi: 10.1097/FJC.0b013e3182676f06..

PMID:
23143654
2.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010
3.

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.

Rao MS.

J Assoc Physicians India. 2010 Feb;58:102-8. Review.

PMID:
20653151
4.

Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.

Gardner SY, Atkins CE, Sams RA, Schwabenton AB, Papich MG.

J Vet Intern Med. 2004 Mar-Apr;18(2):231-7.

5.

Serum angiotensin converting enzyme activity and response to angiotensin I in horses.

Tillman LG, Moore JN.

Equine Vet J Suppl. 1989 Jun;(7):80-3.

PMID:
9118114
6.

Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.

Mochel JP, Fink M, Peyrou M, Soubret A, Giraudel JM, Danhof M.

Pharm Res. 2015 Jun;32(6):1931-46. doi: 10.1007/s11095-014-1587-9. Epub 2014 Dec 2.

PMID:
25446774
7.

Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.

Inglessis N, Nussberger J, Hagmann M, Hiesse-Provost O, Insuasty J, Reid J, Ménard J, Brunner HR.

J Cardiovasc Pharmacol. 1995 Jun;25(6):986-93.

PMID:
7564346
8.
9.

Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.

Gómez-Díez M, Muñoz A, Caballero JM, Riber C, Castejón F, Serrano-Rodríguez JM.

Res Vet Sci. 2014 Aug;97(1):105-10. doi: 10.1016/j.rvsc.2014.06.006. Epub 2014 Jun 12.

PMID:
24972864
10.

A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Claassen K, Willmann S, Eissing T, Preusser T, Block M.

Front Physiol. 2013 Feb 8;4:4. doi: 10.3389/fphys.2013.00004. eCollection 2013.

11.

Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.

Ames MK, Atkins CE, Lee S, Lantis AC, zumBrunnen JR.

Am J Vet Res. 2015 Dec;76(12):1041-50. doi: 10.2460/ajvr.76.12.1041.

PMID:
26618728
12.

Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.

Reams GP, Lal SM, Whalen JJ, Bauer JH.

J Clin Hypertens. 1986 Sep;2(3):245-53.

PMID:
3023555
13.

[Renin-angiotensin-aldosterone system (RAAS) and its pharmacologic modulation].

Giestas A, Palma I, Ramos MH.

Acta Med Port. 2010 Jul-Aug;23(4):677-88. Epub 2010 Jul 30. Review. Portuguese.

14.
15.

[Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].

Abassi Z, Armaly Z, Nakhoul F, Hoffman A.

Harefuah. 2008 Jun;147(6):536-42, 573. Review. Hebrew.

PMID:
18693632
16.

Impact of the renin-angiotensin-aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises.

Hirschl MM, Binder M, Bur A, Herkner H, Woisetschläger C, Bieglmayer C, Laggner AN.

J Hum Hypertens. 1997 Mar;11(3):177-83.

PMID:
9175570
17.

Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.

Dalla Vestra M, Simioni N, Masiero A.

Minerva Endocrinol. 2009 Dec;34(4):333-8. Review.

PMID:
20046162
18.

A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans.

Kawamura M, Imanishi M, Matsushima Y, Akabane S, Kuramochi M, Ito K, Omae T.

Jpn J Pharmacol. 1990 Oct;54(2):143-9.

19.

Clinical profile of eprosartan.

Puig JG, López MA, Bueso TS, Bernardino JI, Jiménez RT; Grupo MAPA-MADRID Investigators.

Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. Review.

PMID:
12766389
20.

Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.

Ferrario CM, Strawn WB.

Am J Cardiol. 2006 Jul 1;98(1):121-8. Epub 2006 May 9. Review.

PMID:
16784934

Supplemental Content

Support Center